Decline Seen in Patients Undergoing Surgery for Colon, Rectal Cancer in 2020
By Elana Gotkine HealthDay Reporter
THURSDAY, April 11, 2024 -- There was a 17.3 percent decrease in the number of patients undergoing surgery for colon and rectal cancer in the first year of the COVID-19 pandemic, according to a study published online March 25 in the Journal of the American College of Surgeons.
Davide Ferrari, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues used data from the National Cancer Database to examine the repercussions of the COVID-19 pandemic on surgical interventions for colorectal cancer in the United States. Data were included for 105,517 adults who underwent surgical procedures for colon and rectal cancer in 2019 and 2020.
The researchers found a 17.3 percent reduction in surgical cases during the first year of the pandemic. More advanced clinical and pathological tumor stages were seen for patients who underwent surgery in 2020 versus those who underwent surgery in 2019. No delay was reported in treatment after diagnosis. Among patients who underwent surgery during the pandemic, worse-stage colon and rectal cancer was seen among African American patients, uninsured patients, and Medicaid beneficiaries; individuals with lower incomes bore the burden of advanced colon cancer.
"The pandemic caught us unprepared, and while social distancing measures helped reduce the immediate impact of the pandemic, they may also have caused unintended consequences, leading to increased mortality in the long term for other causes," the authors write.
One author disclosed ties to Becton Dickinson and Tsumura.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Further Support and Information on COVID-19
Read this next
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.